Patients who responded to intravenous CSA were switched to Neoral for 3 months.

The risk (hazard) of early rejection was higher in the group that received intravenous CSA and N-CSA.

Creatinine levels were also higher between days 13 and 14 in patients who received N-CSA and intravenous CSA.